Currently, a phase 2 multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study to evaluate the efficacy and safety of AK120 (antibody against IL-4Rα) (Figure 3b) subcutaneous injection every 2 weeks for 30 weeks (regimen 1 and regimen 2) versus placebo in 105 adult subjects with moderate-to-severe AD is recruiting subjects in their study and is estimated to be completed in January 2024 [74]. The gene discussed is IL4R; the disease is Alzheimer disease.